Moderna Prices COVID Vaccine Higher than Others

Daniel Fowler
August 9, 2020

Lazio Region announces human trials of "Made in Italy" covid-19 vaccine.

U.S. Food and Drug Administration Commissioner Stephen Hahn said COVID-19 vaccine candidates will be reviewed according to established legal and regulatory standards for medical products, including by an outside advisory committee.

Coronavirus vaccine developer Moderna Inc (NASDAQ: MRNA) has struck its first deal with a government agency, as Switzerland confirmed Friday reports of procuring the mRNA vaccine developed by the company against SARS-CoV-2, Reuters reported.

According to reports, the biotech firm received nearly $1 billion in federal funding to research, develop, and produce a vaccine for the novel coronavirus.

The officials say the first 30 million doses of the planned total of 120 million are expected to be delivered in the first three months of next year if all goes well.

"With this in mind, we are talking to other vaccine makers as well".

53 more cases in B.C., no deaths
Deaths are reported based on when data is received by the Indiana State Department of Health and occurred over multiple days. Sixty-nine people in B.C. who reside outside of Canada have also tested positive for COVID-19.

AstraZeneca, which has been conducting overseas a final-stage clinical trial of its experimental AZD1222 vaccine, has not yet decided whether to inoculate a person once or twice if the vaccine is put into practical use.

AstraZeneca said JCR Pharma will help make a portion of its potential COVID-19 vaccine and it will import shots as part of its deal to supply Japan. It's also a major supplier of hepatitis B vaccine.

Astra has already struck deals to supply hundreds of millions of doses of the experimental vaccine for the United Kingdom, USA and Europe.

Moderna's vaccine is now in phase 3 trials and the company is confident that the vaccine - their first commercial product - will be available by the end of the year.

The two companies will also explore the possibility of cooperation on the vaccine candidate in other markets, AstraZeneca said.

Other reports by